Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Tissue Chips and Drug Development: A Conversation with NCAT’s Dr. Lucie Low

Summary

Lung on a chip from the Wyss Institute at Harvard University
Credit: Daniel Sone Photography

In this episode of The Amazing Things Podcast, we talk to Dr. Lucie Low about tissue chip technology and its potential to change how we develop and test new drugs. Dr. Low is the Scientific Program Manager of the Tissue Chip for Drug Screening Program at the National Center for Advancing Translational Sciences (NCATS), part of the National Institute of Health.

Approximately 30 percent of promising medications have failed in human clinical trials because they are found to be toxic despite promising preclinical studies in animal models. Additionally, about 60 percent of drug candidates fail due to lack of efficacy. These currently unavoidable facts of the drug development process are one reason why there is so much excitement around tissue chips.